Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of .

BACKGROUND

eradication with therapies employing a proton pump inhibitor (PPI) and antimicrobial agents is mainly achieved via bacterial susceptibility to antimicrobial agents and the magnitude of acid secretion inhibition. However, annual eradication rates have greatly declined in Mainland China, and therefore, tailored eradication regimens that inhibit acid secretion and employ optimal antimicrobial agents determined based on gene clip testing may improve eradication rates. This study was aimed at evaluating the efficacy of tailored eradication therapy guided by visual gene clip testing for antibiotic resistance and PPI metabolism genotypes.

METHODS

This prospective study included 244 patients (141 men and 103 women aged 20-79 years) receiving initial treatment for infection. Visual gene clip testing using gastric mucosal specimens was performed to detect antibiotic resistance to clarithromycin conferred by the A2142G and A2143G point mutations of the 23S rRNA gene and to levofloxacin conferred by the Asn87 and Asp91 point mutations of the gene. Patients received a 14-day bismuth quadruple therapy regimen guided by testing for antibiotic resistance and CYP2C19 polymorphisms, and primary eradication was assessed at least 4 weeks after therapy.

RESULTS

strains were successfully isolated from the gastric mucosa tissues of 244 patients. Antibiotic resistant isolates were identified in 63 patients, with clarithromycin resistance observed in 50 patients, levofloxacin resistance in 7 patients, and dual resistance in 6 patients. The PPI metabolic genotype of CYP2C19 was detected in 242 of 244 cases, and 97 cases were categorized as extensive metabolizers, 141 as intermediate metabolizers, and 4 as poor metabolizers. Among the 242 patients who received tailored therapy, the eradication rate was 90.9% (95% confidence interval 87.3%94.6%) in the intention-to-treat analysis and 96.9% (95% confidence interval 94.7%99.2%) in the per protocol analysis.

CONCLUSIONS

Tailored therapy for infection guided by determination of antibiotic resistance and CYP2C19 polymorphism using visual gene chip technology may provide high clinical effectiveness as initial eradication therapy.